BioCentury | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

...DMPK. AMO Pharma Ltd. is planning a pivotal trial testing small molecule GSK3B inhibitor tideglusib (AMO-02...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...models of other KRAS-driven cancers. Noscira S.A. and AMO Pharma Ltd. have the GSK3 inhibitor tideglusib...
BioCentury | Mar 30, 2018
Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

...patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02...
...of once-daily 400 or 1,000 mg oral tideglusib. The company said most patients treated with tideglusib...
...type 1 (DM1) Endpoint: Safety Status: Phase II data Milestone: NA Jennie Walters tideglusib (AMO-02, np-12, Nypta, Zentylor) AMO...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Cancer; autoimmune disease

...inhibitor in additional models of cancer and IBD. Noscira S.A. and AMO Pharma Ltd. have tideglusib...
BioCentury | Oct 31, 2017
Distillery Therapeutics

Cancer

...GSK3 inhibitors in additional lymphoma and melanoma models. Noscira S.A. and AMO Pharma Ltd. have tideglusib...
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Glycogen dependent kinase 3 (GSK3); dyskerin pseudouridine synthase 1 (DKC1)

...in animal models of dyskeratosis congenita. Noscira S.A. and AMO Pharma Ltd. have tideglusib ( AMO-02...
BioCentury | Aug 22, 2016
Clinical News

Tideglusib: Phase II started

...Ltd. , Wonersh, U.K. Noscira S.A. , Madrid, Spain Product: Tideglusib ( AMO-02 ) (formerly NP-12...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

...mouse models of GBM, the GSK3β inhibitor tideglusib decreased tumor growth and increased survival, and tideglusib...
...animal models of other brain cancers. Noscira S.A. and AMO Pharma Ltd. have tideglusib ( AMO-02...
BioCentury | Mar 14, 2016
Emerging Company Profile

AMO's CNS ammunition

...AMO-01's primary competitors. The synthetic analog of glycine-proline-glutamate is in Phase II. AMO's second program, AMO-02...
...DM1, Steinert's disease). AMO-02, an inhibitor of glycogen synthase kinase 3 beta (GSK3B) formerly dubbed tideglusib...
...hyperphosphorylation of tau. Data reported in The Journal of Clinical Investigation in 2012 showed an AMO-02...
BioCentury | Feb 25, 2016
Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3 β (GSK3B); microtubule-associated protein τ (tau; MAPT; FTDP-17)

...inhibitor, in Phase II testing for acute leukemia and pancreatic cancer. AMO Pharma Ltd. has AMO-02...
Items per page:
1 - 10 of 29